Carvin is a global Biopharmaceutical Company

Gallery

Contacts

411 University St, Seattle, USA

engitech@oceanthemes.net

+1 -800-456-478-23

CARVIN MEDICINES IS A
BIOPHARMACEUTICAL COMPANY

DEVELOPING NEXT-GENERATION
NOVEL MEDICINES

About Carvin Medicines

We are on the leading edge of developing treatment protocols for chronic neurogenic disease with novel MEDICINES

In Exclusive Partnership with 37-year old Swiss Pharma company, Alpex Pharma S.A., we are developing FDA and EMA approved drugs and treatment protocols, and leveraging manufacturing expertise by to streamlining formulation, stability, regulatory requirements, and drug registration. Our formulations are designed to mitigate common side effects and improve the drug efficacy by pairing APIs with our patented delivery technologies. 

Targeting Unique Diseases

With unmet patient needs that are typically treated by Opiates, SSRIs, SDRIs, and SNRIs.

Patentable
Products

Intellectual Property based on proprietary formulations and delivery technologies for optimum efficacy and success.

Deploy
& Scale

In full control of the drug development life cycle with immediate capacity to scale and deploy for Clinical Trials and Commercialization.

It is essential to nurture the symbiotic relationship between Novel Clinical Research and Pharma. Our partnership with Alpex Pharma S.A. allows us to be in full control of R&a and commercialization.

0 %

people worldwide suffer from neuropathic pain

0 B+

projected psychedelic Market Size by 2027

0 %

describe their chronic neuropathic pain as 'worse than death'

Our treatments have promise to set the new standard of care for chronic neurogenic disease with poor treatment options and better serve patient needs.

Evidenced APIs

Developing medicines and regiments with existing psychedelic compounds for chronic administration.

Optimum Efficacy

Patented technologies for optimum drug delivery resulting in faster onset, safety and tolerability.

Mitigates Side Effects

Proprietary regimen of micro and low dose formulations eliminate perceptual any physical side effects.

Dosage Regimen

Targeted modality of drug administration that is designed to reach the therapeutic objective for treatment of neurogenic disease.

Our platform, based on 37 years of internal drug development expertise, is applicable to proprietary medicines as well as contracting and/or licensing to third parties for any compound or psychedelic API.

Our flexible partnership structures for R&D, Formulation and Development:

Develop Products
& Licences

Carvin initiates project, and self funds drug development, and fully owns IP. Alpex then licenses to partners for marketing, sales and distribution in global markets.

Co-Develop in Partnership

Partners initiate project with concept and desired API. Alpex develops and commercializes the product. Partner handles marketing, sales & distribution in target markets.

Commercial Contract Partner

Carvin provides full contract development and manufacturing service for every aspect of drug development and manufacturing in a client-fee commercial relationship.

OUR GLOBAL PRESENCE

CARVIN MEDICINES
Canada

Headquarter Holding Company 
Mind and Matter
 

ALPEX PHARMA
SWITZERLAND

Pharmaceutical R&D 
& Commercialization
 

CARVIN MEDICINES
ISRAEL

Clinical R&D 
& Novel Medicines
 

LEADERSHIP TEAM

Experts and pioneers with decades of experience in pain, neuroscience, pharmacology, psychiatry, drug discovery, and pre-clinical and clinical neuropsychiatric drug development.

KEVIN MCKENZIE

Co-Founder President & Director

CAREY KURTIN

Co-Founder & Chairman

DR. SARI SAGIV

Chief Science Officer

DANIEL GELBART

Advisor

MATTHEW KURTIN

Chief Strategy Officer

GABRIELE GRANATA

Development Manager

PALLAVI SHRESTHA

Chief Compliance Officer

DR. BEN H. AMIT

Medical Officer

DR. SARA MELISA

Pre-Clinical Devolopment

MBA Wharton Business School. 20+ years private equity, M&A, Cerberus Capital, Morgan Stanley Private Equity. President & Chairman of Alpex Pharma. Fluent in English, Mandarin, Italian, FRENCH, German (A2)

Boston University, B.S. Business Administration, 10+ years in Private Equity and Capital Markets. Major Shareholder Alpex Pharma in Switzerland. Principal of In Colour Capital, a family office based in Toronto, Canada. Fluent in English and French

Tel Aviv University. Over 20 years of experience in biotech and pharmaceutical development including preclinical and clinical studies, market regulatory affairs and IP. MSc in Genetics and a PhD in Immunology. Fluent in English, Spanish and Hebrew.

ENTREPRENEUR, INVESTOR & CLINICAL SPECIALIST. 15 YEARS OF INTERNATIONAL WORK EXPERIENCE. VARIOUS BOARD MANDATES. CEO AT GELBART AG & ORTHO-TEAM AG, TWO LEADING HEALTHTECH GROUP COMPANIES FOR HUMAN MOBILITY. FLUENT IN GERMAN, ENGLISH AND FRENCH.

University of Southern California, B.S. Business Administration, 10+ years in family office leading private equity and strategic operational development across pharma and technology startup sectors. Fluent in English, French, Swedish, and German (A2)

More than 25 years of experience in pharmaceutical R&D field: formulation, analytical method validation, IP creation, GLP and FDA expert. Developed and patented controlled substances and narcotics for the US and worldwide markets. Fluent in English and Italian

30+ years in Pharmaceutical Research & Development, Regulatory Compliance, Quality Assurance, Quality Control and Operations. Fluent in English and Nepali.

Oxford University and Tel Aviv University. Over 10 years in Medicine, Board certified Psychiatrist, and M.S. in Pharmacology. MAPS certified MDMA for PTSD. Fluent in English and Hebrew

Tel Aviv University, Over 10 years in Medicine. Neuropharmacology and drug development primarly in vivo and pre-clinical trials. Fluent in English and Spanish.